QvinWinter 2016Active☆Watch⊞Compare

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Empowering women. Period.

Qvin is the first and only healthcare service to scientifically prove menstrual blood can test for critical health information – just like a traditional laboratory blood test. Women's health has always been under-prioritized in science. We still operate in a world built by men, for men. It’s why in 2014, Dr. Sara Naseri and Søren Therkelsen started Qvin to research, develop, and patent a product that powers an underserved and understudied population—women. Over 70% of the decisions our doctors make are influenced by blood test results. Every month, 1.8 billion people across the world menstruate. However, the blood our bodies naturally deliver every month has never been explored as a testing source. And yet, menstrual blood has been left unexplored. Qvin is the first and only healthcare service to use period blood as a non-invasive blood test. We exist to give women an easy, insightful way to monitor existing health issues, proactively screen for others, and go into doctor visits more informed and confident of their own health. Our health technology platform helps women manage their health better through a non-invasive blood collection device named the Q-Pad™. All of us at Qvin want to move the study of women forward. We want to close the gender data gap. And we stand for every person who identifies with women, however they define it.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Qvin is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Qvin sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Qvin, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.